What is prognosis of Lung cancer?

O'pka saratoni prognozlari qanday?

O'pka saratoni prognozlari bir nechta omillarga bog'liq, shu jumladan saratonning bosqichi, o'pka saratoni turi va bemorning umumiy sog'lig'i.

Eng keng tarqalgan tur bo'lgan kichik hujayrali bo'lmagan o'pka saratoni, barcha bosqichlar uchun 5 yillik omon qolish darajasi taxminan 18% ni tashkil etadi.

Biroq, agar saraton erta aniqlansa, 5 yillik omon qolish darajasi 57% gacha bo'lishi mumkin. Kichik hujayrali o'pka saratoni kamroq uchraydi, barcha bosqichlar uchun 5 yillik omon qolish darajasi taxminan 7% ni tashkil etadi.

Shuni ta'kidlash kerakki, bu umumiy statistik ma'lumotlar bo'lib, individual natijalar farq qilishi mumkin.

Davolash usullari va tibbiyotdagi yutuqlar yaxshilanishda davom etmoqda va ko'plab bemorlar to'g'ri parvarish va boshqaruv bilan uzoq umr ko'rishlari va hayot sifatini yaxshilashlari mumkin.

Ma'lumotlar

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Martini B: [Lung cancer--epidemiology, prognosis and therapy]. Med Monatsschr Pharm. 2006, 29 (6): 217-21.

Zou T, Liu JY, She L, Yin JY, Li X, Li XP, Zhou HH, Chen J, Liu ZQ: The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Pharmacol. 2020, 11 (): 1029.

Li L, Zhou Q, Luo D, Xu Y, Yang H, Zhang S, Li A, Li H, Lv C: [A study on the relationship between lung cancer cell apoptosis and prognosis in patients with human non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 1998, 1 (2): 70-3.

Feng YY, Yang Y, Wang YY, Bai XX, Hai P, Zhao R: [Hypomethylation of DAPL1 associated with prognosis of lung cancer patients with EGFR Del19 mutation]. Zhonghua Zhong Liu Za Zhi. 2021, 43 (12): 1264-1268.

Xiao Y, Zhu S, Yin W, Liu X, Hu Y: IGFBP-4 expression is adversely associated with lung cancer prognosis. Oncol Lett. 2017, 14 (6): 6876-6880.

Lang J, Zhao Q, He Y, Yu X: Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers. 2018, 23 (6): 518-526.

Mas'uliyatdan voz kechish: tibbiy

Ushbu veb-sayt faqat ta'lim va axborot maqsadlari uchun mo'ljallangan bo'lib, tibbiy maslahat yoki professional xizmatlar ko'rsatmaydi.

Ma'lumotlardan sog'liqni saqlash muammolari yoki kasalliklarni tashxislash yoki davolash uchun foydalanmaslik kerak va shaxsiy tibbiy maslahat so'raganlar litsenziyaga ega bo'lgan shifokor bilan maslahatlashishlari kerak.

Iltimos, savollarga javoblarni ishlab chiqaradigan neyron tarmog'i, ayniqsa, raqamli tarkibga kelganda noto'g'ri ekanligiga e'tibor bering. Masalan, ma'lum bir kasallik bilan kasallangan odamlar soni.

Har doim shifokoringiz yoki boshqa malakali sog'liqni saqlash provayderining maslahatini so'rang. Hech qachon professional tibbiy maslahatni e'tiborsiz qoldirmang yoki ushbu veb-saytda o'qiganingiz sababli uni so'rashni kechiktirmang. Agar siz tibbiy favqulodda vaziyatga duchor bo'lishingiz mumkin deb o'ylasangiz, darhol 911 ga qo'ng'iroq qiling yoki eng yaqin favqulodda vaziyatlar bo'limiga boring. Ushbu veb-sayt yoki uning ishlatilishi bilan hech qanday shifokor- bemor munosabatlari yaratilmaydi. BioMedLib ham, uning xodimlari ham, ushbu veb-saytga hech qanday hissa qo'shuvchi, bu erda taqdim etilgan ma'lumot yoki uning ishlatilishi bilan bog'liq hech qanday bayonot bermaydi.

Mas'uliyatdan voz kechish: mualliflik huquqi

1998-yilgi raqamli ming yillik mualliflik huquqi to'g'risidagi qonun, 17 U.S.C. 512-moddasi (DMCA) Internetda paydo bo'lgan materiallar AQSh mualliflik huquqi to'g'risidagi qonun bo'yicha o'z huquqlarini buzadi deb hisoblaydigan mualliflik huquqi egalari uchun choralar ko'rsatadi.

Agar siz bizning veb-saytimiz yoki xizmatlarimiz bilan bog'liq bo'lgan har qanday tarkib yoki material sizning mualliflik huquqingizni buzadi deb yaxshi ishonchga ega bo'lsangiz, siz (yoki sizning vakilingiz) bizga tarkib yoki materialni olib tashlashni yoki unga kirishni to'xtatishni so'rab xabar yuborishingiz mumkin.

Xabarlar yozma ravishda elektron pochta orqali yuborilishi kerak (elektron pochta manzili uchun "Muloqot" bo'limiga qarang).

DMCA sizning da'vo qilingan mualliflik huquqi buzilganligi to'g'risidagi xabarnomangizda quyidagi ma'lumotlarni o'z ichiga olishini talab qiladi: (1) da'vo qilingan mualliflik huquqi buzilgan asarning tavsifi; (2) da'vo qilingan mualliflik huquqi buzilgan tarkibning tavsifi va bizga tarkibni topishga imkon beradigan etarli ma'lumotlar; (3) siz uchun aloqa ma'lumotlari, shu jumladan sizning manzilingiz, telefon raqami va elektron pochta manzili; (4) siz tomonidan da'vo qilingan tarzda tarkib mualliflik huquqi egasi yoki uning vakili yoki har qanday qonun tomonidan ruxsat berilmaganligiga ishonchingiz borligi to'g'risidagi bayonot;

(5) siz tomonidan yolg'on guvohlik berish jazosi ostida imzolangan, bildirishnomadagi ma'lumotlar to'g'ri ekanligi va siz buzilgan deb da'vo qilingan mualliflik huquqlarini amalga oshirish vakolatiga ega ekanligingiz to'g'risidagi bayonot;

va (6) mualliflik huquqi egasining yoki mualliflik huquqi egasi nomidan harakat qilishga vakolatli shaxsning jismoniy yoki elektron imzosi.

Yuqoridagi barcha ma'lumotlarni kiritmaslik sizning shikoyatingizni ko'rib chiqishni kechiktirishi mumkin.

Aloqa qilish

Iltimos, har qanday savol / taklif bilan bizga elektron pochta xabarini yuboring.

What is prognosis of lung cancer?

The prognosis of lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the overall health of the patient.

Non-small cell lung cancer, which is the most common type, has a 5-year survival rate of about 18% for all stages combined.

However, if the cancer is caught early, the 5-year survival rate can be as high as 57%. Small cell lung cancer, which is less common, has a 5-year survival rate of about 7% for all stages combined.

It is important to note that these are general statistics and individual outcomes may vary.

Treatment options and advancements in medicine continue to improve, and many patients can live longer and have a better quality of life with proper care and management.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.